Literature DB >> 11239444

Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.

D Schrama1, P thor Straten, W H Fischer, A D McLellan, E B Bröcker, R A Reisfeld, J C Becker.   

Abstract

A recombinant antibody-lymphotoxin-alpha fusion protein induced an adaptive immune response protecting mice from melanoma. Importantly, this fusion protein elicited the formation of a lymphoid-like tissue in the tumor microenvironment containing L-selectin+ T cells and MHC class II+ antigen-presenting cells, as well as B and T cell aggregates. Furthermore, PNAd+/TCA4+ high endothelial venules were observed within the tumor, suggesting entry channels for naive T cell infiltrates. Over the course of therapy, a marked clonal expansion of certain TCR specificities occurred among tumor-infiltrating lymphocytes that displayed reactivity against melanoma cells and the TRP-2(180-188) peptide. Consequently, naive T cells may have been recruited to as well as primed and expanded in the lymphoid-like tissue induced by the lymphotoxin-alpha fusion protein at the tumor site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239444     DOI: 10.1016/s1074-7613(01)00094-2

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  65 in total

1.  IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.

Authors:  Maya Eisenring; Johannes vom Berg; Glen Kristiansen; Elisabeth Saller; Burkhard Becher
Journal:  Nat Immunol       Date:  2010-10-10       Impact factor: 25.606

Review 2.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 3.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.

Authors:  Si-Si Wang; Wei Liu; Dalam Ly; Hao Xu; Limei Qu; Li Zhang
Journal:  Cell Mol Immunol       Date:  2018-04-08       Impact factor: 11.530

Review 4.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

Review 5.  Tissue-resident dendritic cells and diseases involving dendritic cell malfunction.

Authors:  Keqiang Chen; Ji Ming Wang; Ruoxi Yuan; Xiang Yi; Liangzhu Li; Wanghua Gong; Tianshu Yang; Liwu Li; Shaobo Su
Journal:  Int Immunopharmacol       Date:  2016-02-22       Impact factor: 4.932

Review 6.  B lymphocytes and cancer: a love-hate relationship.

Authors:  Grace J Yuen; Ezana Demissie; Shiv Pillai
Journal:  Trends Cancer       Date:  2016-12

Review 7.  Inflammation-induced lymphangiogenesis and lymphatic dysfunction.

Authors:  Shan Liao; Pierre-Yves von der Weid
Journal:  Angiogenesis       Date:  2014-01-22       Impact factor: 9.596

8.  Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

Authors:  Luca Szalontay; Andrew V Schally; Petra Popovics; Irving Vidaurre; Awtar Krishan; Marta Zarandi; Ren-Zhi Cai; Anna Klukovits; Norman L Block; Ferenc G Rick
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

Review 10.  New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Authors:  Mark L Tykocinski; Aoshuang Chen; Jui-Han Huang; Matthew C Weber; Guoxing Zheng
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.